+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Expired

Jon J. van Rood Award

European Group for Blood and Marrow Transplantation

The Jon van Rood award was created in the name of the late Jon van Rood, a long active immunologist who made seminal discoveries and observations in the field of cell and tissue transplants, in particular haematopoietic cell transplantation. While haematopoietic cell transplantation remains a historical and canonical form of cell transplant and in many of its applications in immunotherapy of haematological malignancies, many recent developments have led to the approval and commercialization of innovative industry-manufactured medicinal products, some of which have resulted in the engineering of autologous or allogeneic immune effector cells with clinical efficacy in some disease subsets. To recognise these important changes, the scope of the Jon van Rood Award is now expanded to cover immunological aspects of haematopoietic cell transplantation as well as new developments in the design and evaluation of immune effector cell therapies.

EBMT Cellular Therapy & Immunobiology Working Party (CTIWP) is pleased to offer this prestigious (5,000€) award for outstanding contributions in the field of haematopoietic transplantation immunology, immunogenetics, tolerance, graft-vs-leukaemia/tumour effects, immune monitoring and development of innovative therapeutic approaches based on the engineering of immune effector cells. The selection will be undertaken by a distinguished international jury.

The award will be presented on an annual basis during the Cellular Therapy and Immunobiology Working Party Scientific Session at the EBMT Annual Meeting.

Important information to qualify for the award:

The paper should be published or accepted for publication during the year 2025.
The candidates should not be older than 40 years on December 31st, 2025.
The Award is restricted to the first author of the paper or one of the first co-authors with equal contribution*. (*In case of equal contribution/shared first authorship, a letter of approval of the other co-first author should be submitted.)
The Academic paper is in English.

Application guidelines

Applications for the award should include the following:

Letter of application/ motivational letter (maximum one page)
Curriculum vitae (CV) of the applicant (including year of birth)
Academic paper

Please send your application through this link:

https://www.surveymonkey.com/r/JJvanRood2026

Deadline to apply: 23rd January 2026

The award of 5,000€ is generously supported by the EBMT with an unrestricted educational grant.

AI Based Application Success Predictor

1. Strong alignment with EBMT scientific priorities & a specific Working Party

Projects that clearly fall within one Working Party’s scope (e.g., Acute Leukemia WP, Cellular Therapy WP, Complications & Quality of Life WP) consistently perform better.
Why it predicts success:

WPs are the scientific engines of EBMT and drive grant ranking.

Endorsement by the WP signals both scientific importance and feasibility.

Top predictor: Early WP engagement → higher scores.

2. Demonstrated feasibility using EBMT Registry data or multicentre participation

Historically funded EBMT projects almost always:

Use EBMT Registry data, or

Include multiple EBMT centres with recruitment commitments.

Why it predicts success:

EBMT values high-impact, generalizable research.

Registry-based or multicentre designs show scalability and public health relevance.

Common pattern in successful awards: A clear description of registry variables, expected sample size, and data completeness.

3. A rigorous, EBMT-appropriate statistical plan

Because EBMT research deals heavily with HSCT outcomes (OS, DFS, relapse, NRM, GVHD), reviewers look for:

Competing-risk analyses

Time-to-event methods

Handling of missing/heterogeneous registry data

Pre-specified endpoints

Realistic power/sample-size estimates

Predictor: Studies with a statistician experienced in transplant outcomes score much higher.

4. Clear clinical impact and relevance to transplantation practice

Reviewers favour projects that show:

How results could change guidelines

How findings would improve transplant decision-making

Value for the broad EBMT community

Applications that explicitly define translational potential or practice-changing outcomes tend to be funded.

5. Previous EBMT involvement or demonstrated collaborative capacity

Review panels consistently reward PIs or teams that show:

Prior EBMT abstracts/publications

Ongoing collaboration with EBMT WPs

Experience with real-world HSCT research

Predictor: A connected and collaborative PI/team increases trust that the study will be delivered and published.

6. Feasible scope, timelines, and workload (given volunteer-based WP structure)

EBMT WPs rely heavily on volunteer time; thus, proposals that are:

Overly ambitious

Logistically heavy

Dependent on unrealistic centre participation

…are typically rejected.

Predictor: A concise, executable plan with a realistic workload is strongly favoured.

7. Clear dissemination and publication plan

Successful proposals typically outline:

Target journals

Abstract submission to EBMT Annual Meeting

How the WP community will be informed

Reviewers want assurance that the work will be visible and impactful.

Specialties

Immunology

Others

Eligibility Requirements

Sponsor Details

Sponsor Institute/Organizations: European Group for Blood and Marrow Transplantation

Sponsor Type: Corporate/Non-Profit

Address: Rijnsburgerweg 10, 2333 AA Leiden

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity